Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ibrutinib in Chronic GVHD

February 8th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.

Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

February 6th 2024

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

February 6th 2024

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Patient Profile 1: A 72-Year-Old Man With MDS

February 6th 2024

Andrew Brunner, MD, presents the profile of a 72-year-old man with MDS and the panel offers their initial impressions on the case, focusing on the treatment decisions.

Current Treatment Options in Second-line MCL

February 6th 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in MCL

February 6th 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

February 6th 2024

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Enasidenib Plus Venetoclax Yields High Response Rates Targeting IDH2 Mutations in R/R AML

February 5th 2024

The combination of the first-in-class inhibitor enasidenib plus venetoclax has generated excitement targeting IDH2 mutations in relapsed/refractory AML.

Understanding Malignancy Risks With the Use of CAR T-cell Therapies

February 5th 2024

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.

CAR T-Cell Therapy as a Second-Line Treatment for LBCL

February 5th 2024

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

February 2nd 2024

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

February 2nd 2024

Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.

Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

February 2nd 2024

Panelists evaluate PFS, OS, and the prognostic significance of negative MRD.

Patient Case Studies of GvHD

February 2nd 2024

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

Monitoring Patients on Myelofibrosis Treatment

February 2nd 2024

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Treating Patients with Myelofibrosis and Anemia

February 2nd 2024

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Ruxolitinib in Chronic GVHD

February 2nd 2024

The expert panel explores the approval of ruxolitinib for chronic GVHD based on the REACH3 trial. The panel highlights the trial’s outcomes, long-term follow-up data, and the evolving shift in clinical practices.

Switching to Second Line Treatment in Chronic GVHD

February 2nd 2024

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

January 31st 2024

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

Dr Battiwalla on Outpatient CAR T-Cell Therapy Administration in Hematologic Malignancies

January 31st 2024

Minoo Battiwalla, MD, discusses findings from a study of outpatient care after CAR T-cell therapy in patients with hematologic malignancies.